StockNews.com upgraded shares of ProQR Therapeutics (NASDAQ:PRQR – Free Report) from a hold rating to a buy rating in a research report sent to investors on Monday morning. A number of other equities analysts also recently weighed in on the company. Raymond James cut their target price on ProQR Therapeutics from $5.00 to $4.00 and […]
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) has earned a consensus rating of “Buy” from the five research firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in […]
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) has been assigned an average rating of “Buy” from the five brokerages that are covering the firm, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have covered the stock in the last year is $3.72. Several […]
Shares of ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) have received a consensus recommendation of “Buy” from the five ratings firms that are covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have covered the stock in the last year […]
ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) has been given an average rating of “Buy” by the five brokerages that are presently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have updated their coverage on the stock in […]